Key Takeaways for CVS Health Stock as of August 2026
- Post-Earnings Slide: CVS Health stock has fallen about 10% since its August 5 earnings beat, sliding from $104 to $94 as investors focused on a cautious preliminary 2027 outlook.
- Street Split: CVS Health stock carries 18 buys, 6 outperforms, and 3 holds against a $116 mean target, 24% above the current price.
- Model Upside: TIKR’s mid-case model values CVS Health stock at $132, implying a 41% total return by December 2030.
- Steady Climb: The Street’s mean target has risen every quarter since mid-2025, from $80 to $116.
Why CVS Health Stock Keeps Sliding After a Beat-and-Raise Quarter
CVS Health (CVS) stock has dropped from a pre-earnings close of $104 on August 4 to $94 by August 19, even though the company beat Wall Street’s second-quarter estimates and raised its full-year adjusted earnings guidance to a range of $7.90 to $8.10 from $7.30 to $7.50. Shares fell nearly 6% on August 5 alone, the day management delivered the news, and CVS Health stock has not recovered since.
The quarter gave bulls plenty to like. Revenue reached $106.1 billion against a $100.1 billion estimate, adjusted earnings per share hit $2.58 versus a $1.85 consensus, and Aetna’s medical benefit ratio, the share of premiums spent on patient care, improved to 87.4% from 89.9% a year earlier. What spooked investors instead was the first look at 2027.
CFO Brian Newman addressed that setup directly on the Q2 earnings call: “While we would not normally comment on 2027 consensus this early in the year, an outlook of at least $8.44, consistent with current consensus, appears reasonable at this juncture.” A floor instead of a raise, paired with warnings of Caremark client attrition and continued 340B drug-pricing pressure, gave the market a reason to sell a quarter that beat on every line.
The result is CVS Health stock trading further below where it sat two months ago than the underlying numbers suggest it should, a gap the Street has been widening its targets against rather than closing.
CVS Health Stock’s Target Keeps Climbing While the Price Falls Behind
CVS Health stock carries a decisively bullish tilt from the sell side. Of the analysts issuing ratings, 18 call it a buy, 6 rate it an outperform, and 3 have it at hold, with no sell or underperform ratings on the board. The mean target across 25 estimates stands at $116, 24% above the $94 close, and the high estimate reaches $148.
That mean target has not fallen in any of the last six quarters tracked, climbing from $80 in June 2025 to $95 by year-end and on to $116 by mid-August 2026. The price has been far choppier. It fell to $72 in March, spiked to $103 in June, then gave most of that gain back.
The Target/Close ratio tightened to 102% in June, implying almost no perceived upside at the stock’s peak, before widening back to 124% as CVS Health stock slid through the summer. A steadily climbing target against a volatile price says the Street has kept faith in the earnings trajectory even as the market re-rates the stock lower on the 2027 caveats from the call.
TIKR Values CVS Health Stock at $132, Pricing In a Margin Recovery
TIKR’s mid-case model values CVS Health at $132 by December 2030, implying a 41% total return from the current price of $94, or 8% annualized over 4.4 years.
That annualized return sits ahead of what a mature managed-care and pharmacy operator typically prices in, reflecting a name still working through a multiyear margin recovery rather than one already re-rated to peer multiples.
The gap is reachable because the Street’s own numbers point the same direction. A $116 mean target has risen every quarter even as CVS Health works through the 340B and Caremark retention headwinds flagged for 2027, and this quarter’s beat is the kind of execution the model is betting continues.
The multiple backs that up. CVS Health stock trades at 11.5x forward earnings, down from 13.6 times in June and close to its own 12-month average near 11.5x, so TIKR’s target isn’t underwriting a re-rating so much as a return to the multiple investors were already paying before the August pullback.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
The multiple backs that up. CVS Health stock trades at 11.5x forward earnings, down from 13.6 times in June and close to its own 12-month average near 11.5x, so TIKR’s target isn’t underwriting a re-rating so much as a return to the multiple investors were already paying before the August pullback.
